TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17457131

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulation guidance (group NS)
Number of subjects: 60
Study: 15764423

Group type: EXPERIMENTAL
Intervention: Aftercare
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Psychological variables and attendance at religious services
Number of subjects: 194
Study: 11981600

Group type: EXPERIMENTAL
Intervention: 120 mg methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg methadone
Number of subjects: 0
Study: 10321133

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8124803

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography (0.84 mg/kg over 10 hours)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Exercise ECG (maximal symptom-limited bicycle test)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography and exercise ECG
Number of subjects: 429
Study: 2917589

Group type: EXPERIMENTAL
Intervention: 5‐methoxypsoralen (5‐MOP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 5472756

Group type: EXPERIMENTAL
Intervention: Intravenous heparin in a therapeutic dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31271554

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3 g/day for 12 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 27320903

Group type: EXPERIMENTAL
Intervention: ROPScore
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: CHOP ROP
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: WINROP
Number of subjects: 445
Study: 26218818

Group type: EXPERIMENTAL
Intervention: Breast-feeding with maternal holding
Number of subjects: 128

Group type: COMPARATOR
Intervention: Maternal holding without breast-feeding
Number of subjects: 128
Study: 23980090

Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg orally once per day plus best supportive care (BSC)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 395
Study: 20881867

Group type: EXPERIMENTAL
Intervention: Different blood pressure-lowering regimens
Number of subjects: 201566

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatments
Number of subjects: 201566

Group type: EXPERIMENTAL
Intervention: Additional blood pressure reduction in hypertensive patients
Number of subjects: 201566
Study: 19501658

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 0
Study: 16845347

Group type: EXPERIMENTAL
Intervention: Transfer technique
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 163

Group type: COMPARATOR
Intervention: Reference arm
Number of subjects: 163
Study: 12782900

Group type: EXPERIMENTAL
Intervention: Stepped-care treatment (counseling and nicotine patch therapy)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Minimal intervention (no additional treatment)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Stepped-care treatment
Number of subjects: 254
Study: 11778284

Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Partial laryngectomy
Number of subjects: 423
Study: 9084868

Group type: EXPERIMENTAL
Intervention: Active digital mobile radio telephone (0.05 mW/cm2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Inactive digital mobile radio telephone (GSM) system
Number of subjects: 34
Study: 7901058

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g administered 12 hours before surgery
Number of subjects: 50
Study: 2419945

Group type: EXPERIMENTAL
Intervention: iloprost (3 infusions of 5 hours each)
Number of subjects: 33

Group type: COMPARATOR
Intervention: iloprost (2 ng/kg/min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: PGI2 (5 ng/kg/min)
Number of subjects: 33
Study: 30175373

Group type: EXPERIMENTAL
Intervention: Cervical ripening balloon (CRB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandins (PGE)
Number of subjects: 0
Study: 27575731

Group type: EXPERIMENTAL
Intervention: rAd‐p53 transfer combined with radiotherapy (PRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: rAd‐p53 transfer
Number of subjects: 69
Study: 24928796

Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22012969

Group type: EXPERIMENTAL
Intervention: Rituximab 2×1000 mg + MTX
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Rituximab 2×500 mg + MTX
Number of subjects: 755

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 755
Study: 20487584

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich beverage (test beverage)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 18591315

Group type: EXPERIMENTAL
Intervention: L-isoleucine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L-isoleucine and L-valine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L-valine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of L-isoleucine and L-valine
Number of subjects: 100
Study: 15967450

Group type: EXPERIMENTAL
Intervention: 600 microg of intravaginal misoprostol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 800 microg of intravaginal misoprostol
Number of subjects: 114
Study: 12429856

Group type: EXPERIMENTAL
Intervention: High AGE diet (H-AGE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low AGE diet (L-AGE)
Number of subjects: 24
Study: 10518249

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 200 mg/I.M. weekly for six months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO) continued
Number of subjects: 33
Study: 7488444

Group type: EXPERIMENTAL
Intervention: Alteplase (100 mg over three hours)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Streptokinase (1.5 MU over 60 minutes)
Number of subjects: 37
Study: 1785705

Group type: EXPERIMENTAL
Intervention: 2.5 ml of a 0.5% bupivacaine solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 ml of a 0.125% bupivacaine solution in normal saline
Number of subjects: 30
Study: 6920253

Group type: EXPERIMENTAL
Intervention: Pereflat (3 tablets daily for 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (3 tablets daily for 3 days)
Number of subjects: 50
Study: 31974282

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 312

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 312
Study: 30591959

Group type: EXPERIMENTAL
Intervention: Vaccine alone (arm B)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vaccine plus all-trans-retinoic acid (arm C)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Observation (arm A)
Number of subjects: 69
Study: 27984535

Group type: EXPERIMENTAL
Intervention: Polymyxin-B hemoperfusion
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 213
Study: 26112091

Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin and 5‐fluorouracil induction chemotherapy followed by carboplatin concurrent chemoradiotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: conventional concurrent chemoradiotherapy
Number of subjects: 36
Study: 23760634

Group type: EXPERIMENTAL
Intervention: Life‐Steps program
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 168
Study: 20603439

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin-based chemotherapy
Number of subjects: 57
Study: 19710081

Group type: EXPERIMENTAL
Intervention: Xylitol (5 to 6 grams, three exposures per day from chewing gum or candies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses of xylitol (from toothpaste studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylitol as a sweetener in low amounts in foods
Number of subjects: 0
Study: 18318099

Group type: EXPERIMENTAL
Intervention: Sodium salicylate iontophoresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy and regular medications
Number of subjects: 20
Study: 15965673

Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate (SH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1% carboxymethylcellulose (CMC)
Number of subjects: 22
Study: 11988609

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (SBP)
Number of subjects: 17398

Group type: EXPERIMENTAL
Intervention: Low systolic blood pressure (SBP)
Number of subjects: 17398

Group type: COMPARATOR
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 17398
Study: 9534826

Group type: EXPERIMENTAL
Intervention: Intensive clinical case management (ICM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard community care (control)
Number of subjects: 70
Study: 7625342

Group type: EXPERIMENTAL
Intervention: 3870-kJ (925-kcal)/d diet for the first 16 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Balanced-deficit diet of 5029-6279 kJ (1200-1500 kcal)/d thereafter
Number of subjects: 66
Study: 1978212

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (less than or equal to 3 g/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 226841

Group type: EXPERIMENTAL
Intervention: Premarin tablets, 1.25 mg per day for 3 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31743566

Group type: EXPERIMENTAL
Intervention: Inlay bone grafting technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Onlay bone grafting technique (control)
Number of subjects: 16
Study: 28299489

Group type: EXPERIMENTAL
Intervention: 1064‐nm Q‐switched neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser (QSNYL)
Number of subjects: 29
Study: 25839204

Group type: EXPERIMENTAL
Intervention: 4-day empowerment training
Number of subjects: 257

Group type: COMPARATOR
Intervention: 4-day entrepreneurial training (control)
Number of subjects: 257
Study: 23760009

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (PHRT; n = 15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (PHET; n = 13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Time-control group (PHTC; n = 15)
Number of subjects: 43
Study: 21162656

Group type: EXPERIMENTAL
Intervention: Q‐TER (water‐soluble coenzyme Q10) for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 60
Study: 19487381

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interferon alfa (IFN‐alpha) 9 MU subcutaneously thrice weekly
Number of subjects: 750
Study: 17185049

Group type: EXPERIMENTAL
Intervention: Racemic carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enantiomers of carvedilol
Number of subjects: 0
Study: 15272670

Group type: EXPERIMENTAL
Intervention: Volume-based objective function optimization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial solutions based on minimization/maximization of dose to critical structures and targets
Number of subjects: 0
Study: 11384628

Group type: COMPARATOR
Intervention: Low-isoflavone diet (8 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-isoflavone diet (65 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-isoflavone diet (130 mg/day)
Number of subjects: 32
Study: 8995343

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (1000 mg/day) for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 25
Study: 8425703

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa therapy for chronic hepatitis C
Number of subjects: 616
Study: 3300755

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg orally followed at 35 min by i.v. saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral placebo followed at 35 min by i.v. diazepam 10 mg (Diazemuls)
Number of subjects: 40
Study: 29744950

Group type: EXPERIMENTAL
Intervention: Tailored evidence-based intervention (leaflet and letter)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tailored evidence-based intervention (leaflet)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control leaflet about ageing well
Number of subjects: 65
Study: 28606084

Group type: EXPERIMENTAL
Intervention: Cinnamon (6 capsules, 3 g daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Wheat flour (6 capsules, 2.5 g daily)
Number of subjects: 116
Study: 25641704

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Educational Intervention (EI)
Number of subjects: 221
Study: 23683393

Group type: EXPERIMENTAL
Intervention: Short-stretch bandages applied weekly for 2 weeks, followed by a class II elastic stocking for 2 weeks (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Light stocking ('liner') for 1 week followed by superimposing a second stocking for 3 weeks (group B)
Number of subjects: 28
Study: 20885188

Group type: EXPERIMENTAL
Intervention: 2‐[nitrooxy]ethyl 2‐amino‐3‐methylbutanoate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18426844

Group type: EXPERIMENTAL
Intervention: Praneem polyherbal vaginal tablet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15894775

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg orally twice daily for two days
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 156
Study: 12629589

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10765098

Group type: EXPERIMENTAL
Intervention: RPLND + 2 cycles of chemotherapy (arm A)
Number of subjects: 187

Group type: COMPARATOR
Intervention: 3-4 cycles of primary chemotherapy (arm B)
Number of subjects: 187
Study: 8653870

Group type: EXPERIMENTAL
Intervention: Troponin T levels measured in the initial 24 hours
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Age, hypertension, number of antianginal drugs, and ECG changes at rest
Number of subjects: 976
Study: 1462882

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6746961

Group type: EXPERIMENTAL
Intervention: Empathy algorithm
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group of classmates
Number of subjects: 23
Study: 31526916

Group type: EXPERIMENTAL
Intervention: Low-cost standing desk
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 29625956

Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 36
Study: 26828710

Group type: EXPERIMENTAL
Intervention: Posttraumatic amnesia (PTA) duration greater than 1 week
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Posttraumatic amnesia (PTA) duration of 1 to 7 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Posttraumatic amnesia (PTA) duration greater than 7 days
Number of subjects: 330
Study: 23916017

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) session
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) session
Number of subjects: 104
Study: 22613054

Group type: COMPARATOR
Intervention: Buspirone (60 mg/day)
Number of subjects: 60
Study: 20102552

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 74
Study: 17870203

Group type: EXPERIMENTAL
Intervention: Rhubarb extract (20 mg kg(‐1) once a day) for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (starch) for 6 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rhubarb extract
Number of subjects: 80
Study: 15802870

Group type: EXPERIMENTAL
Intervention: Tirofiban and clopidogrel pretreatment for 48 hours before intervention
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Tirofiban and clopidogrel pretreatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Untreated group (no tirofiban and clopidogrel)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 14666763

Group type: EXPERIMENTAL
Intervention: Qi-supplementing and blood-activating (QSBA) therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neurotrophic agents
Number of subjects: 68
Study: 10953421

Group type: EXPERIMENTAL
Intervention: Thyroxin treatment for six months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9064258

Group type: EXPERIMENTAL
Intervention: Nodal stage disease (12 specimens)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nodal stage disease
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal palmar fascia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Stage IV disease
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nodal or cord-stage of Dupuytren's disease
Number of subjects: 42
Study: 1624967

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study: 6385316

Group type: EXPERIMENTAL
Intervention: Transcatheteric partial splenic embolization (PSE)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Splenectomy (SX)
Number of subjects: 53
Study: 29931571

Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking (CXL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional corneal cross-linking (CXL)
Number of subjects: 23
Study: 29460388

Group type: EXPERIMENTAL
Intervention: pdFX (plasma-derived factor X concentrate) 25 IU kg-1 on-demand
Number of subjects: 10
Study: 26808034

Group type: EXPERIMENTAL
Intervention: 1:1:1 ratio of plasma-platelet-red blood cell
Number of subjects: 680

Group type: COMPARATOR
Intervention: 1:1:2 ratio of plasma-platelet-red blood cell
Number of subjects: 680
Study: 24258152

Group type: EXPERIMENTAL
Intervention: Half-course tourniquet strategy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Whole-course tourniquet strategy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 22997787

Group type: EXPERIMENTAL
Intervention: Acupoint application combined with routine treatment of western medicine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine treatment of western medicine
Number of subjects: 63
Study: 19756027

Group type: EXPERIMENTAL
Intervention: Kilned oats
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Unkilned oats
Number of subjects: 31
Study: 17521315

Group type: EXPERIMENTAL
Intervention: Normoxic training (N)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoxic training (H)
Number of subjects: 8
Study: 11097143

Group type: EXPERIMENTAL
Intervention: Gastro-resistant tablets (500 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prolonged-release tablets (1000 mg single dose)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral administrations of mesalazine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rectal administration of mesalazine suppository
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous administration of mesalazine
Number of subjects: 200
Study: 9506005

Group type: EXPERIMENTAL
Intervention: Cefodizime (2-g intravenous dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpirome (2-g intravenous dose)
Number of subjects: 0
Study: 8478756

Group type: EXPERIMENTAL
Intervention: Aggressive physical therapy for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: No physical therapy (Control)
Number of subjects: 50
Study: 3510422

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 29153250

Group type: EXPERIMENTAL
Intervention: Mental skills and FLS training (MSC group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Only FLS training (control group)
Number of subjects: 24
Study: 26898621

Group type: EXPERIMENTAL
Intervention: Ramucirumab + Docetaxel (RAM + DTX)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo + Docetaxel (PL + DTX)
Number of subjects: 1253
Study: 25143491

Group type: EXPERIMENTAL
Intervention: e-beam sterilization (high dose 17.1 to 21.0 kGy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: e-beam sterilization (low dose 9.2 to 12.2 kGy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: gamma irradiation (17.1 to 21.0 kGy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: nonsterilized controls
Number of subjects: 80
Study: 22442431

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 198

Group type: COMPARATOR
Intervention: Interferon β‐1a (IFNβ‐1a)
Number of subjects: 198
Study: 20528696

Group type: EXPERIMENTAL
Intervention: SFA + HA/GTR
Number of subjects: 24

Group type: COMPARATOR
Intervention: SFA
Number of subjects: 24
Study: 18761816

Group type: EXPERIMENTAL
Intervention: Atomization inhalation of budesonide and terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 15908196

Group type: EXPERIMENTAL
Intervention: docetaxel 85 mg/m2 i.v. on day 1 and cisplatin 40 mg/m2 i.v. on days 1 and 2 (arm A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: cisplatin 100 mg/m2 i.v. on day 1 followed by 5‐fluorouracil 1000 mg/m2 in 24 h continuous infusion for 5 d (arm B)
Number of subjects: 83
Study: 12595863

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pravastatin (40 mg daily)
Number of subjects: 130
Study: 10563619

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201